证券代码：870199 证券简称：倍益康 公告编号：2025-035 四川千里倍益康医疗科技股份有限公司 舆情管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 四川千里倍益康医疗科技股份有限公司于 2025 年 4 月 17 日召开了第三届董 事会第二十三次会议，会议审议通过了《关于制定公司<舆情管理制度>的议案》， 表决结果：同意 8 票；反对 0 票；弃权 0 票。本议案无需提交股东大会审议。 二、 制度的主要内容，分章节列示： 四川千里倍益康医疗科技股份有限公司舆情管理制度 第一章 总则 第一条 为提高四川千里倍益康医疗科技股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立健全舆情监测、评估、预警及快速反应和应急处置机 制，及时、妥善处理各类舆情对公司股价、商业信誉及正常生产经营活动造成的 影响，切实保护投资者和公司的合法权益，根据《中华人民共和国公司法》、《中 华人民共和国证券法》、《上市公司信息披露管理办法》等相关法律法规、规范性 文件以及《四川千里倍益康 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-020 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（易阳） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2024 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 会会议 1 次、独立董事专门会议 1 次，未发生需董事会战略与发展委员会、董事 会提名委员会审议事项。本人作为董事会审计委员会主任委员积极出席董事会审 计委员会会议以及独立董事专门会议，切实履行审计委员与独立董事职责， ...

证券代码：870199 证券简称：倍益康 公告编号：2025-022 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（王伦刚） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 （一）出席董事会、股东大会的情况 2024 年度公司共召开董事会会议 7 次，股东大会 3 次。本人积极参加了公 司召开的董事会及股东大会，认真审阅相关资料，参与各项议题的讨论并提出合 理建议，以严谨的态度行使表决权 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-021 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（聂采现） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2024 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 （一）出席董事会、股东大会的情况 2024 年度公司共召开董事会会议 7 次，股东大会 3 次。本人积极参加了公 司召开的董事会及股东大会，认真审阅相关资料，参与各项议题的讨论并提出合 理建议，以严谨的态度行使表决权 ...

Innovation and Product Development - The company added 141 new patents during the reporting period[4] - The portable deep muscle massager was recognized as one of the first "Chengdu Industrial Fine Products" by local authorities on March 1, 2024[4] - A new subsidiary, Foshan Beika Electronic Commerce Co., Ltd., was established to expand online sales channels on March 14, 2024[4] - A wholly-owned subsidiary, Tibet Yanluo Technology Co., Ltd., was set up on May 29, 2024, to promote oxygen therapy products in high-altitude regions[4] - The company received medical device registration certificates for several products, including the biological stimulation feedback instrument and the medium-frequency therapy instrument, on September 18 and December 31, 2024, respectively[4] - The portable pneumatic massage system obtained FDA 510(k) registration on October 8, 2024[4] - The company is developing a series of new medical devices, including a pelvic floor rehabilitation device and a portable pressure massage system, with several products already receiving medical device registration[86] - The company has achieved significant advancements in its product lines, including the introduction of smart control technology in its high-frequency electrotherapy products[86] - The company has expanded its product line with the launch of a new portable oxygen machine, which meets high-altitude supply needs and is currently in mass production[87] - The company has developed a new series of medical oxygen machines designed to alleviate oxygen deficiency, ensuring stable oxygen concentration above 90%[87] - The company has introduced a new line of portable oxygen machines that can switch between pulse and continuous modes, catering to outdoor and high-altitude travel needs[87] - The company has enhanced its rehabilitation product offerings with the introduction of portable biofeedback devices, meeting the needs for pelvic floor and neurological rehabilitation[88] - The company has developed a new series of ultrasound and electrical stimulation therapy devices, which are designed for pain rehabilitation[88] - The company has optimized its magnetic therapy products to meet clinical demands for various diseases, achieving industry-leading technical indicators[88] - The company has developed 8 different models of massage guns, enhancing market competitiveness and brand recognition through continuous product iteration[175] - The new massage gun features a variable amplitude adjustment system, allowing for a massage depth of 4-10mm, catering to diverse user needs[175] - The mid-frequency electrotherapy device allows for independent output across 4 channels, enabling simultaneous treatment of multiple areas[175] - The company’s products are positioned above average in several key performance indicators compared to similar products in the market[176] - The company is focused on enhancing user experience through innovative designs and advanced technology in its product offerings[175] Financial Performance - The company's operating revenue for 2024 was CNY 291.23 million, a decrease of 12.78% compared to CNY 333.89 million in 2023[24] - The net profit attributable to shareholders for 2024 was CNY 27.78 million, down 36.70% from CNY 43.89 million in 2023[24] - The gross profit margin improved to 37.99% in 2024 from 36.73% in 2023[24] - Total assets increased by 4.71% to CNY 690.47 million in 2024, compared to CNY 659.43 million in 2023[26] - Total liabilities rose by 17.19% to CNY 168.37 million in 2024, up from CNY 143.67 million in 2023[26] - The company's cash flow from operating activities decreased by 47.00% to CNY 29.99 million in 2024, compared to CNY 56.58 million in 2023[26] - The weighted average return on equity based on net profit attributable to shareholders was 5.33% in 2024, down from 8.49% in 2023[24] - The company reported a net profit margin decline, with a net profit growth rate of -36.70% in 2024 compared to -37.33% in 2023[26] - The company achieved operating revenue of CNY 291,228,708.87 and a net profit attributable to shareholders of CNY 27,781,140.47 during the reporting period[41] - Total assets as of December 31, 2024, amounted to CNY 690,471,403.90, with a net cash flow from operating activities of CNY 29,985,257.05[41] - Cash and cash equivalents increased by CNY 35,542,800, representing a growth of 56.96% compared to the previous period[47] - Construction in progress rose by CNY 124,147,400, reflecting a 99.40% increase due to ongoing investments in the Chengdu smart manufacturing base[47] - Long-term borrowings increased by CNY 24,992,000, a rise of 249.92%, primarily due to mortgage loans for property purchases[47] - The company experienced a 151.99% increase in financial expenses, primarily due to reduced bank deposit interest income[53] - The impairment loss on assets was recorded at CNY 396.46 thousand, reflecting a new provision for inventory depreciation[53] - The company reported a significant increase in contract liabilities, which rose by 60.65% to CNY 2.73 million, indicating a rise in customer prepayments[51] - Domestic revenue fell by 38.27% to CNY 142.99 million, while overseas revenue increased by 45.00% to CNY 148.23 million[62] - Revenue from muscle massagers, the company's main product, reached CNY 227.32 million, representing 78.85% of total operating income, highlighting the company's dependency on a single product[103] Market and Industry Trends - The global rehabilitation medical device market is expected to reach USD 50 billion by 2025, with a compound annual growth rate of approximately 7%[43] - The Chinese rehabilitation medical device market is projected to reach CNY 123.15 billion by 2030, indicating significant growth potential[43] - The health consumption trend is evolving, with consumers increasingly seeking preventive care and wellness solutions rather than just medical treatment[161] - The global wellness industry is projected to reach $5 trillion in 2021 and is expected to grow to approximately $7 trillion by 2025, with a compound annual growth rate (CAGR) of 9.90%[161] - China's health industry is targeted to exceed 8 trillion yuan by 2020 and reach over 16 trillion yuan by 2030, with an estimated CAGR of 7.18%[163] - The demand for rehabilitation medical devices is expected to create a market need of approximately 120 billion yuan from 2021 to 2030, based on a projected shortfall of 400,000 rehabilitation beds[167] - The number of rehabilitation medicine beds in China was reported at 306,846 by the end of 2020, indicating significant growth potential in the sector[167] - The integration of new technologies such as big data, artificial intelligence, and wearable devices is driving innovation in the health industry, leading to the development of new products and services[161] - The rehabilitation medical device market is categorized into assessment devices, training devices, and therapy devices, each playing a crucial role in patient recovery[164] - The Chinese government is actively promoting the development of the health industry as a pillar of the national economy, emphasizing the importance of innovation and technology[163] - The rehabilitation medical device market is expected to see increased investment, with an estimated 300,000 yuan per bed for rehabilitation equipment in hospitals[167] - The home medical device market is experiencing a steady increase in penetration rate, supported by aging population trends and rising health awareness[168] - The home rehabilitation medical device segment is anticipated to become a new driving force for the development of home medical devices due to increased consumer demand for self-care and remote diagnosis services[170] - The consumer-grade smart hardware market in China is projected to reach approximately 1.3 trillion RMB by 2025, driven by the growth of IoT products and advancements in digital infrastructure[174] Corporate Governance and Compliance - The company has implemented various audit procedures to ensure the accuracy and reliability of its revenue recognition policies[90] - The company has confirmed that there are no relationships affecting the independence of its auditing firm, ensuring objective and accurate financial reporting[91] - The company has maintained compliance with corporate governance regulations, ensuring investor rights and information transparency[189] - The company has established a complete modern corporate governance system, ensuring shareholder rights and participation in decision-making processes[190] - The company strictly followed legal procedures for major operational decisions and investments, with no violations reported during the period[191] - The company ensured that all meeting procedures complied with legal and regulatory requirements, including notice and voting processes[196] - The company has committed to transparency in its fundraising and usage reports, ensuring compliance with regulations[195] - The company has established an Investor Relations Management System to enhance communication with investors and improve transparency, ensuring timely disclosure of relevant information[198] - The Audit Committee reviewed the internal audit department's work plan and provided guidance, ensuring effective execution of internal control systems[200] - The company has committed to maximizing shareholder value through improved corporate governance and investor relations practices[198] Research and Development - R&D expenditure for the current period is CNY 17,103,465.59, accounting for 5.87% of operating revenue, compared to CNY 20,400,005.98 and 6.11% in the previous period[82] - The proportion of R&D personnel in the total workforce is stable at approximately 15.81%, with a total of 79 R&D staff[83] - The company’s R&D investment capitalized rate remains at 0%, indicating a focus on immediate expense recognition rather than capitalization[83] - The company has implemented a comprehensive R&D management system in compliance with ISO13485 standards, ensuring quality control throughout the product development process[181] - The company has established a risk management plan for product development, identifying and controlling safety-related risks[181] - The top five R&D projects incurred a total expenditure of 9,875,509.29 yuan during the reporting period, with the variable amplitude deep muscle massager being the highest at 3,671,000.50 yuan[184] - The company has obtained multiple domestic and international patent authorizations for its products, including the portable pressure massage system which has passed FDA510(K) approval[180] Employee and Shareholder Relations - The company has a total of 502 employees at the end of the reporting period, down from 544 at the beginning, reflecting a net decrease of 42 employees[150] - The board of directors consists of 8 members, while the supervisory board has 3 members, and there are 5 senior management personnel[150] - The total number of employees in the R&D department decreased from 86 to 79, with 16 new hires and 23 departures during the reporting period[150] - The company has implemented a comprehensive employee training program focusing on job skills, professional knowledge, and safety[151] - The company has no retired employees for which it needs to bear costs during the reporting period[151] - The total number of shares held by the board members and senior management is 41,211,072, accounting for 60.44% of the total shares[147] - The company’s financial compensation for directors and senior management is based on their positions and individual performance[149] - The company has adopted an employee stock ownership plan for core technical personnel to align their interests with the company's development[105] - The company has established a reasonable profit distribution plan to share operational results with shareholders while ensuring sustainable development[95] Strategic Focus and Future Plans - The company plans to continue focusing on the rehabilitation technology sector, enhancing its product offerings in health and wellness[38] - The company plans to implement a dual-driven strategy of "ODM + own brand" to enhance brand exposure and customer reach[41] - The company aims to leverage new technologies such as big data and AI to drive innovation in health products and services[44] - The company plans to increase investment in "medical + consumer" resources to enhance its position as a global leader in comprehensive rehabilitation technology[98] - The company aims to expand its overseas market presence and sales channels to strengthen its core product advantages in the industry[99] - The company plans to achieve a production capacity of 203,000 units per year for various therapeutic products by December 31, 2025, with a total investment of 403.184 million yuan[179] - The company is focusing on building an integrated online and offline marketing network to enhance customer data management and marketing strategies[42] - The company has not encountered any significant uncertainties affecting its future business strategy during the reporting period[100]

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.4079 | 0.6444 | -36.7 | 1.8288 | | 每股净资产（元） | 0 | 7.54 | -100 | 10.65 | | 每股公积金(元) | 4.92 | 4.91 | 0.2 | 6.85 | | 每股未分配利润(元) | 1.37 | 1.31 | 4.58 | 2.42 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.91 | 3.34 | -12.87 | 3.91 | | 净利润(亿元) | 0.28 | 0.44 | -36.36 | 0.7 | | 净资产收益率(%) | 5.33 | 8.49 | -37.22 | 37.41 | 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2060.47万股，累计占流通股比： 55.39%，较上期变化： -87.00万 股。 | 名称 持有 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-023 四川千里倍益康医疗科技股份有限公司 董事会关于独立董事独立性自查情况专项报告 根据独立董事向董事会提供的关于独立性情况的自查报告，结合其他相关资 料，董事会就独立董事的独立性形成如下结论： （一）独立董事及其配偶、父母、子女、具有主要社会关系的人员未在公司 或公司附属企业任职； （二）独立董事及其配偶、父母、子女未直接或间接持有公司已发行股份百 分之一以上，不是公司前十名股东中的自然人股东； （三）独立董事及其配偶、父母、子女不是直接或间接持有公司已发行股份 百分之五以上的股东，未在公司前五名股东任职； （四）独立董事及其配偶、父母、子女未在公司控股股东、实际控制人的附 属企业任职； （五）独立董事不是公司及公司控股股东、实际控制人或者其各自的附属企 业有重大业务往来的人员，未在有重大业务往来的单位及其控股股东、实际控制 人任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其各自附属企 业提供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中介机 1 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-024 四川千里倍益康医疗科技股份有限公司 董事会审计委员会 2024 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 2024 年，四川千里倍益康医疗科技股份有限公司（以下简称"公司"或"本 公司"）董事会审计委员会（以下简称"审计委员会"）根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司独立董事管理办法》《北京证券交 易所上市公司持续监管指引第 1 号——独立董事》以及《公司章程》《审计委员 会工作细则》等的规定，忠实勤勉地履行了工作职责。现将审计委员会 2024 年 度履职情况报告如下。 一、审计委员会基本情况 2022 年 3 月 30 日，公司召开第二届董事会第十五次会议，审议通过了《关 于设立董事会专门委员会暨选举委员的议案》，公司在董事会下设立董事会审计 委员会。审计委员会由 3 名董事组成，分别为独立董事易阳、独立董事王伦刚、 董事蔡秋菊，其中召集人由具有会计专业资格的独立董事易阳担任。 根据 ...

拟续聘 2025 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：870199 证券简称：倍益康 公告编号：2025-034 四川千里倍益康医疗科技股份有限公司 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 服务及收费情况：信永中和会计师事务所（特殊普通合伙）已为公司提供 9 年审计服务，上期审计收费 40 万元，本期审计收费 50 万元 一、拟续聘会计师事务所的基本情况 （一）机构信息 公司拟聘任信永中和会计师事务所（特殊普通合伙）为 2025 年年度的审计 机构。 1.基本信息 拟聘任的会计师事务所：信永中和会计师事务所（特殊普通合伙） 会计师事务所名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 2024 年 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-033 四川千里倍益康医疗科技股份有限公司 审计委员会对会计师事务所履行监督职责情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 根据《公司法》《证券法》《国有企业、上市公司选聘会计师事务所管理办法》 等规定和要求，四川千里倍益康医疗科技股份有限公司（以下简称"公司"）董 事会审计委员会对公司 2024 年度审计机构信永中和会计师事务所（特殊普通合 伙）（以下简称"信永中和"）履行了监督职责，现将董事会审计委员会对会计 师事务所履行监督职责情况汇报如下： 一、2024 年度审计机构的基本情况 （一）会计师事务所基本情况 信永中和会计师事务所（特殊普通合伙）成立于 2012 年 3 月 2 日，注册地 址北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层，首席合伙人为谭小青先 生。截至 2024 年 12 月 31 日，信永中和合伙人数量为 259 人，注册会计师 1780 人，签署过证券服务业务审计报告的注册会计师人数超过 70 ...